Crispr Therapeutics AG is a pioneering biotechnology company specializing in gene editing. Its primary function is to advance the development and application of CRISPR/Cas9 technology, which allows fo... Crispr Therapeutics AG is a pioneering biotechnology company specializing in gene editing. Its primary function is to advance the development and application of CRISPR/Cas9 technology, which allows for precise, directed changes to genomic DNA. The company's work focuses on harnessing this revolutionary tool to potentially treat a range of genetic diseases, including blood disorders, certain cancers, and conditions related to the immune system. Crispr Therapeutics is at the forefront of the biopharmaceutical industry, fundamentally altering how genetic disorders might be cured or managed. By collaborating with various academic and industry leaders, the company strives to bring innovative therapies from the research phase to clinical trials and, eventually, to patients in need. As a part of the broader biotechnology sector, Crispr Therapeutics plays a crucial role in the advancement of personalized medicine, making significant strides in the potential to significantly alter disease outcomes and improve patient health globally.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

CRISPR Therapeutics is not subject to EU Taxonomy reporting

Based on current regulatory requirements, CRISPR Therapeutics is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review CRISPR Therapeutics's data?

Start your 30-day free trial to request a data review for CRISPR Therapeutics.

Start Free Trial

Legal Center Contact Us